ArticleFrontiers in pediatrics2022

Significant advantages for first line treatment with TNF-alpha inhibitors in pediatric patients with inflammatory bowel disease - Data from the multicenter CEDATA-GPGE registry study.

Merle Claßen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.